Pfizer’s Gene Therapy Asset Chases UniQure/CSL’s Hemgenix After Pivotal Hemophilia B Success
Executive Summary
Pfizer’s fidanacogene elaparvovec has hit the mark in a Phase III hemophilia B trial just a month after rival UniQure’s Hemgenix won US approval, with Pfizer’s plans for regulatory action raising the stakes for Hemgenix.
You may also be interested in...
Value-Based Agreements On The Cards For UniQure/CSL’s $3.5m Hemophilia B Gene Therapy
While Hemgenix has courted criticism since its $3.5m price tag was unveiled, a drug pricing expert has told Scrip discounts and value-based agreements could make the therapy more palatable to payers.
UniQure/CSL Set To Launch First Hemophilia B Gene Therapy Next Year At Record Price
The firms’ gene therapy Hemgenix has won a US thumbs up for the treatment of hemophilia B and plans are underway for a US launch with a big price tag that experts agree should pay off in the long-term.
Deal Watch: Pfizer Lays Groundwork In Gene Therapy
Pfizer expands its position in rare diseases in a collaboration with Spark Therapeutics and also licenses a pair of preclinical oncology candidates from Belgium’s iTeos Therapeutics. Meanwhile, Shire gets $15 million in research funding from the Cystic Fibrosis Foundation to help advance a novel aerosolized therapy addressing the underlying cause of CF.